Cisplatin (cis-diaminedichloroplatinum (II)) is an alkylating agent used in different types of cancers, for example ovarian, testicular, lung, bladder (Fig. 1). The success of cisplatin has aroused great interest in the development of new metal complexes to diagnose and therapy. The important aspect in this field was the discovery of the cisplatin’s mechanism of action and pharmacokinetic parameters. 

Fig. 1. The structure of cisplatin.

      This paper presents the interaction of the cisplatin with the main transporting protein in plasma -albumin, and it’s modified by glycation and high level fatty acids forms. The problem is regarding the initial stage of fates of the drug in the body (LADME) - binding protein-drug.

      In this work cisplatin binding were studied using atomic emission spectrometry with inductively coupled plasma (ICP-AES) and differential pulse stripping voltammetry (DPSV). The results suggest that one mole of the protein binds four moles of cisplatin. The investigations were also conducted on the glycation modified albumin and in the presence of fatty acids excess. During hyperglycemia and/or high levels of fatty acids is observed a strong reduction in the affinity of cisplatin to albumin (one mole of protein binds about the half less of the complex of cisplatin). It can be a result of global structural changes associated with the fatty acids binding and local changes in subdomain IIA caused by glycation. Studies have shown that modifying the structure of albumin may increase the amount of free, pharmacologically active fraction of the drug, which could have an impact on therapy.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/28021 must be provided.

1. Interaction of an potential copper(I) radiopharmaceuticals with human serum albumin
2. Effects of nonenzymatic glycosylation and fatty acids presence on meloxicam binding to human serum albumin
3. Phase Diagram for the Tl₂Te - In₂Te₃ System Determined by Thermal Analysis and Concentration Cell EMF Measurements